Investor Relations

Investor Relations

Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Recent Releases

May 11, 2012
Myrexis Appoints New Executive Management Team in Alignment With Strategic Initiatives

May 10, 2012
Myrexis Reports Third Quarter Fiscal Year 2012 Results

View all releases »

Stock Chart
Stock price graph
3 Mo.   6 Mo.   1 Yr.
Stock Quote
Myrexis, Inc.
Price: 2.57
Change: -0.06
Day High: 2.65
Day Low: 2.56
Volume: 74,500
Delayed at least 20 minutes.
Provided by eSignal.